Viagra significantly boosted Pfizer’s revenue. Sales peaked at over $2 billion annually in the early 2000s. This substantial contribution directly impacted Pfizer’s stock price, driving significant growth.
While Viagra’s sales have declined since the patent expiration, it remains a significant contributor to Pfizer’s overall portfolio. The drug continues to generate considerable revenue, offering financial stability and supporting further investment in R&D.
Investors should consider Pfizer’s historical dependence on Viagra’s performance when analyzing their stock. Understanding the drug’s revenue trajectory provides valuable context for evaluating the company’s past and future financial health. Analyze Pfizer’s financial statements to see the specific contribution of Viagra to their bottom line over the years.
Remember to consult financial news sources and analyst reports for the latest data and insights on Pfizer’s performance and Viagra’s ongoing contribution.
